Amgen

This study is checking the long-term safety of a drug called avacopan for people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. About 300 adults who need treatment for a new diagnosis or flare-up will take avacopan or a placebo. The…

This phase 3 trial tests whether maridebart cafraglutide, a drug that may help with weight loss, can reduce sleep apnea episodes in 250 adults who are overweight or obese and not using a breathing machine. Participants receive either the drug or a placebo for 52 weeks. The main g…

This phase 3 trial is testing whether adding the experimental drug xaluritamig to standard abiraterone helps men with metastatic castration-resistant prostate cancer live longer. About 750 participants who have not yet had chemotherapy will be randomly assigned to receive either …

This study tests whether a new drug combo (sotorasib plus chemotherapy) works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has a specific KRAS G12C gene change and low PD-L1 levels. About 750 adults wh…

This phase 3 trial tests whether a subcutaneous (under-the-skin) injection of pegloticase works as well as the standard intravenous (IV) infusion for people with uncontrolled gout. About 270 adults will receive either the shot or the IV, both with weekly methotrexate. The goal is…

This early-phase trial is testing a new drug called AMG 436, alone or with other cancer treatments, in adults with advanced solid tumors that have high microsatellite instability or mismatch repair deficiency. The main goals are to check safety, find the best dose, and see how th…

This study tests two medications, inebilizumab and blinatumomab, in adults with active lupus (with kidney inflammation) or hard-to-treat rheumatoid arthritis. The goal is to see if these drugs are safe and can help control the diseases. About 220 people will take part. This is no…

This early-phase trial is testing whether combining two experimental drugs, tarlatamab and ZL-1310, with or without the immunotherapy durvalumab, can safely shrink tumors in people with small cell lung cancer that has worsened after standard treatment. About 160 adults will take …

This early-phase trial is testing a new drug called xaluritamig (AMG 509) in 40 adults with metastatic castration-resistant prostate cancer, a type that has spread and no longer responds to hormone therapy. The main goal is to check the drug's safety and how it moves through the …

This Phase 3 study tests whether the drug apremilast (Otezla) can safely reduce joint inflammation and pain in children aged 5 to 17 with active juvenile psoriatic arthritis. About 60 participants will receive either apremilast or a placebo pill for 16 weeks. The main goal is to …

This early-stage study tests a new drug called AMG 509, alone or with other medicines, in people with a type of advanced prostate cancer that no longer responds to hormone therapy. The main goals are to check safety and how the body processes the drug. About 479 participants will…

This study tests a new medicine, maridebart cafraglutide, for adults with obstructive sleep apnea who are overweight or obese and already use a CPAP machine. The goal is to see if the drug can reduce breathing pauses during sleep and help with weight loss over 52 weeks. About 250…

This phase 3 trial tests whether the drug maridebart cafraglutide (MariTide) can help people with obesity or overweight lose weight and keep it off over the long term. Participants who completed an earlier trial will receive either the drug or a placebo. The study measures weight…

This early-stage study tests a new drug, AMG 127, to see if it is safe for people. It involves 162 healthy adults and people with type 2 diabetes. Researchers will give single or multiple doses and watch for side effects. This is a first step to see if the drug can be developed f…

This early-stage trial is testing a drug called xaluritamig, given alone or with a hormone blocker, before men with intermediate- or high-risk prostate cancer have their prostate removed. The main goal is to see if the treatment is safe and does not interfere with surgery. About …

This early-stage trial tests a new oral drug called AMG 410, alone or with other medicines, in adults with advanced solid tumors that have KRAS gene changes. The study aims to find a safe dose and check for side effects. About 434 participants will take part across multiple dose …

This Phase 3 study tests whether adding the targeted drug sotorasib and another drug called panitumumab to standard chemotherapy (FOLFIRI) works better than standard chemo alone (with or without bevacizumab) for people with metastatic colorectal cancer that has a specific KRAS G1…

This phase 3 trial tests whether a new drug called ABP 938 works as well as the approved treatment Eylea HD for wet age-related macular degeneration, a leading cause of vision loss. About 304 people aged 50 and older with untreated wet AMD will receive injections of either drug i…

This study tests whether the drug apremilast (Otezla) can reduce painful mouth ulcers in children aged 2 to 17 with Behçet's disease. About 60 participants will receive either apremilast or a placebo for 12 weeks to see if the drug works better than a dummy pill. The goal is to h…

This phase 3 study is testing whether a new drug called maridebart cafraglutide (MariTide) can reduce the risk of heart attacks, strokes, and death in people with heart disease who are overweight or obese. About 12,800 participants will receive either the drug or a placebo, added…

This phase 3 trial tests whether switching from common GLP-1 weight-loss drugs to a new medication called maridebart cafraglutide can help adults with obesity or overweight maintain their weight loss. About 300 participants who have already lost at least 10% of their body weight …

This study tests a drug called AMG 732 in 30 adults with thyroid eye disease who either did not respond to treatment or saw their symptoms return after a previous study. The main goal is to see if the drug can reduce eye bulging by at least 2 millimeters without worsening the oth…

This study is for people with advanced solid tumors who have a specific gene change (KRAS G12C) and are already doing well on sotorasib (with or without panitumumab) from a previous Amgen trial. It allows them to keep receiving the treatment while doctors monitor safety and side …

This early-phase trial is testing a drug called xaluritamig (AMG 509) in 50 adults, adolescents, and children with Ewing sarcoma that has relapsed or not responded to prior treatments. The main goals are to find a safe dose and check for side effects. Researchers will also measur…

This phase 3 trial tests whether adding the drug tarlatamab to standard chemotherapy and immunotherapy helps people with extensive-stage small-cell lung cancer live longer. About 330 participants will be randomly assigned to receive either the new combination or standard treatmen…

This study tests a drug called inebilizumab in 15 children aged 2 to 17 with generalized myasthenia gravis, a condition that causes muscle weakness. The main goals are to see how the drug moves through the body, how safe it is, and whether it helps control symptoms. The drug is g…

This early-phase trial is testing a new immunotherapy drug called xaluritamig combined with standard hormone therapies (darolutamide or abiraterone) in 60 men with metastatic hormone-sensitive prostate cancer. The main goal is to check safety and tolerability, while also looking …

This phase 3 trial tests whether maridebart cafraglutide (MariTide) can reduce heart failure events like hospitalizations and urgent visits in people with obesity and a specific type of heart failure (preserved or mildly reduced ejection fraction). About 5,056 participants will r…

This early-phase trial is testing a drug called tarlatamab, given as a shot under the skin, for people with extensive stage small cell lung cancer that has worsened after standard chemotherapy. The main goals are to check safety and side effects, and to see how the drug behaves i…

This real-world study is following 7,000 Chinese adults with established heart disease to see if adding Repatha® (a cholesterol-lowering injection) to their usual care reduces major cardiovascular events like heart attacks, strokes, and heart-related death. Participants are eithe…

This study follows children and teens with osteogenesis imperfecta (brittle bone disease) who previously received romosozumab in an earlier trial. Researchers will monitor 71 participants for side effects over time. The goal is to see if the drug is safe for long-term use in this…

This early-stage trial is testing a new drug called AMG 513 in 80 adults with obesity. The main goal is to see if the drug is safe and how the body handles it. Participants will receive either the drug or a placebo by injection, and researchers will monitor for side effects and m…

This study tests whether the drug maridebart cafraglutide can reduce liver fat and body weight in adults who are overweight or obese and have high liver fat. Participants will also follow a reduced-calorie diet and increase physical activity. The trial involves 180 adults and las…

This early-phase trial is testing whether combining two drugs, tarlatamab and AB248, is safe and tolerable for people with extensive stage small cell lung cancer that has worsened after at least one prior treatment. About 380 adults will take part. The main goals are to check for…

This study looks at the long-term safety of a drug called dazodalibep for people with Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth. About 844 people who completed a prior phase 3 study will receive the drug for up to 48 more weeks. The main goal is to …

This Phase 3 trial tests olpasiran, a drug that lowers lipoprotein(a), a genetic risk factor for heart disease. About 406 adults with stable heart disease and high Lp(a) will receive either olpasiran or a placebo. The main goal is to see if olpasiran reduces non-calcified plaque …

This phase 3 trial tests the drug etelcalcetide (Parsabiv) in 24 children aged 2 to 17 with secondary hyperparathyroidism due to chronic kidney disease who are on hemodialysis. The goal is to see if the drug can safely lower parathyroid hormone levels and improve mineral balance.…

This phase 3 trial tests etelcalcetide (Parsabiv) in 56 children aged 28 days to under 18 years who have secondary hyperparathyroidism and chronic kidney disease and are on hemodialysis. The drug aims to lower parathyroid hormone levels and improve mineral balance. Participants r…

This study tests a drug called inebilizumab in 15 children aged 2 to 17 with neuromyelitis optica spectrum disorder (NMOSD), a rare condition where the immune system attacks the optic nerves and spinal cord. The drug aims to reduce relapses by targeting certain immune cells. Rese…

This study looks at the long-term safety of the drug apremilast in children aged 2 and older with Behçet's disease (causing mouth ulcers) or aged 5 and older with juvenile psoriatic arthritis. About 48 kids who finished a previous study will take apremilast for up to 52 more week…

This phase 3 study tests whether the drug olpasiran can prevent first major heart events (like heart attacks) in 11,000 people aged 50+ who have high levels of lipoprotein(a), a genetic risk factor. Participants receive either olpasiran or a placebo as a shot under the skin. The …

This phase 1 trial is testing a single dose of the investigational drug AMG 691 in healthy Chinese and Japanese adults aged 18 to 60. The goal is to understand how the drug moves through the body and to check its safety and tolerability. Participants will receive one subcutaneous…

This study follows 60 women with neuromyelitis optica spectrum disorder (NMOSD) who received UPLIZNA during pregnancy or within 6 months before conception. Researchers will collect data on pregnancy outcomes, including birth defects, preterm birth, and infant development over 10 …

This study follows pregnant women with migraine who take Aimovig (erenumab-aooe) to see if the drug increases the risk of major birth defects. Researchers will compare their babies to those of women with migraine who did not take Aimovig. The goal is to gather real-world safety d…